Iovance Biotherapeutics Inc. diskutieren
Iovance Biotherapeutics Inc.
WKN: A2DT49 / Symbol: IOVA / Name: Iovance Biotherapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
8,52 €
-3,13 %
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $29.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $17.00 price target on the stock, up previously from $11.00.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $29.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $29.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $30.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at HC Wainwright from $38.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $12.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at HC Wainwright from $38.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Chardan Capital from $29.00 to $34.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Piper Sandler from $14.00 to $18.00. They now have an "overweight" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $13.00 to $19.00. They now have a "buy" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Wells Fargo & Company from $17.00 to $22.00. They now have an "overweight" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Barclays PLC from $18.00 to $22.00. They now have an "overweight" rating on the stock.
Ratings data for IOVA provided by MarketBeat
Neueste Beiträge
StockNews_com in MPLX L.P. diskutieren